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Objective. Examine the impact of comorbid depression on adherence to disease-modifying therapy (DMT) for multiple sclerosis
(MS).Methods.Aretrospective databasewasusedtoidentifypatientswithMStreated withaDMT. PatientswithMSandcomorbid
depressionwere matched to patients withMS only.Adherence to DMT wasproxied by the medicationpossessionratio (MPR)and
multivariate regressions were used to examine the association between comorbid depression and adherence to DMT. Results.
Patients with comorbid depression had a 10 point lower MPR (P<0.01) and were less likely to achieve a MPR of at least
80% (odds ratio (OR) = 0.55; 95% conﬁdence interval (CI) 0.42–0.74) than those without depression. While treatment with
an antidepressant generally had no signiﬁcant impact on the likelihood of achieving an MPR threshold of 80% (OR = 1.32;
95% CI 0.50–3.48), adherence to antidepressant therapy guidelines were associated with improved adherence to DMT therapy.
Conclusions. MS patients with comorbid depression were approximately half as likely to be adherent to their DMT relative to
patients with MS without depression. Although treatment with antidepressant therapy generally did not improve the likelihood of
adherence, treatment with antidepressants for at least 6 months was associated with better adherence to DMT.
1.Introduction
Multiple sclerosis (MS) is the most common disabling neu-
rological condition for young adults and adolescents in the
United States [1]. Approximately 400,000 Americans have
MS, and everyweek about 200 people are diagnosed with the
disease [2].While theresults of theexisting burden-of-illness
studiesconductedfor MSin the UnitedStatesvary according
to the data sources used [3], they all report substantial
economic impacts of MS, both to the individual and to the
nation. The cost of each MS relapse has been reported to
be approximately $12,870 [4]. The average cost of MS for
the individual patient, each year, is anywhere from $12,879
(2004 USD) [5] to $34,000 (1994 USD) [6]. These ﬁgures
translate to a national cost of $5.2 billion ($12,879 × 400,000
Americans diagnosed with MS) [5] to $6.8 billion (based on
prevalence ﬁgures used by the authors of [6], annually.
While MS is incurable, Food and Drug Administration-
(FDA-) approved disease-modifying therapies (DMTs) have
been shown to reduce the rate of relapse and to slow disease
progression [7, 8]. However, medication can only work if it
is taken. Lack of medication adherence has been shown to be
associated with increased patient morbidity, poorer quality
of life, and increased ﬁnancial strain on health care institu-
tions[9].Inaddition,research hasalsoshown thatadherence
is generally suboptimal among patients with MS [10–13].
One factor that has been shown to negatively impact ad-
herence among patientswithMS isthe presence ofcomorbid
depression [10, 13]. This factor may aﬀect a large portion
of the MS population, since depression is common among
individuals with MS. Research has shown that up to one-
half of all MS patients [14, 15] have comorbid depression,
and that the prevalence of this comorbidity is three-times
the rate of major depression and psychiatric comorbidity
in community-based samples and greater than the rate of
depression among patients with otherneurological disorders
[16].
Given the potential impact of depression on MS adher-
ence as well as the relatively large prevalence of this comor-
bidity, this analysis was designed to quantify the impact of2 Multiple Sclerosis International
comorbid depression and antidepressant therapy on adher-
ence to disease-modifying therapy (DMT) for MS. Given the
previous literature reporting a connection between mood
disorders and adherence among patients with MS [10],
we hypothesized that a diagnosis of comorbid depression
would have a negative impact on adherence. In addition,
we examined the impact of receipt of antidepressant therapy
on adherence to MS adherence. In so doing, the analysis
quantiﬁes the association between comorbid depression,
receipt of antidepressants, and adherence to MS therapy.
2.Materialsand Methods
2.1. Data. The MedStat MarketScan Commercial Claims
and Encounters (CCAE) and Medicare (MDCR) databases
provided the data for these analyses, which focused exclu-
sively on data from January 1, 2004 through March 25,
2009. These retrospective insurance claims databases include
private sector health data from approximately 100 pay-
ers and contain data on clinical utilization, expenditures,
and enrollment across inpatient, outpatient, prescription
drug, and carve-out services. The deidentiﬁed databases are
fully Health Insurance Portability and Accountability Act
(HIPAA) compliant and link paid claims and encounter data
to detailed patient information across sites and types of
p r o v i d e r so v e rt i m e .
2.2. Sample. To be considered for inclusion in the study,
patients had to have received at least one diagnosis of MS
(ICD-9-CMcode of340.xx)and a disease modifying therapy
(DMT), with the ﬁrst such receipt in the date window
identiﬁed as the index date and the initial DMT received
identiﬁed as the intent-to-treat (ITT) medication. Patients
were excluded if they were diagnosed with pregnancy (ICD-
9-CM code of 630.xx-676.xx, V22.2x, or V22.3x) over the
time period from 6 months prior to the index date (i.e.,
the pre-period) through 12 months after index date (i.e.,
the postperiod). Finally, patients were required to have
continuous insurance coverage from the start of the pre-
period through the end of the post-period. These criteria
resulted in a sample of 11,780 individuals (Figure 1).
Given the above cohort of individuals, the group was
then subdivided into patients who had neither a diagnosis
of depression nor the receipt of an antidepressant in the
pre-period (i.e., MS Only) and those who were identiﬁed
with comorbid depression (i.e., MS & Depression). To be
identiﬁed as having depression in the 6 month pre-period,
patients were required to receive 2 or more outpatient
or 1 or more inpatient diagnoses of depression (ICD-9-
CM of 296.2x, 296.3x, or 311.xx), or 1 or more diagnoses
of depression and 1 or more ﬁlled prescriptions for an
antidepressant. For patients who did not receive an antide-
pressant, the requirement of one inpatient diagnosis or two
outpatient diagnoses of depression was utilized to insure
that a patient was diagnosed with depression and not simply
screened for depression. Furthermore, such an algorithm
is commonly used to identify diagnoses in retrospective
databases [17, 18]. There were 4,479 individuals diagnosed
with MS who had no evidence of depression (MS Only)
and 448 individuals identiﬁed as having MS and comorbid
depression (MS & Depression). Of the 448 individuals with
MS and Depression, 379 individuals received at least one
prescription for an antidepressant.
Given the above sample of patients, three subgroups of
patients were examined. One group consisted of a matched
groupof patients with MS onlytothose with MS and depres-
sion, where patients were matched 1:1 without replacement
based upon age, sex, region of residence, year of index date,
and intent-to-treat medication. This matching resulted in
a successful match rate of 97% and a ﬁnal sample of 876
individuals: 436 individuals with MS and depression and
436 individuals with MS only. In addition to examining
patients with MS only to those with MS and depression,
we also examined adherence by comparing patients who
were diagnosed with depression but did not receive an
antidepressant (N = 59) to those diagnosed with depression
who did receive an antidepressant (N = 359). These two
groups were matched 1:1 without replacement using the
same factors used to match the MS Only group to the MS &
Depression group. This process resulted in a ﬁnal sample of
76 individuals: 38 individuals with a diagnosis of depression
and no receipt of an antidepressant and 38 individuals who
were both diagnosed with depression and ﬁlled at least one
prescription for an antidepressant. The third group com-
pared patients who received an antidepressant based upon
adherence to treatment guidelines for use of antidepressants
[19].Speciﬁcally,patientswere dividedbased uponreceipt of
at least a 6-month supply of antidepressants. Again, the two
cohorts were matched 1:1 without replacement, with a ﬁnal
sample of142 individuals: 71 treated accordingto guidelines,
and 71 who received less than 6 months of antidepressants.
2.3. Measuring Adherence. While adherence generally mea-
sures the extent to which a patient acts in accordance with
the prescribed interval and dose of a dosing regimen [20],
such information is not typically available in a retrospective
claims database. As such, adherence is “...operationalized
in retrospective assessments as the number of doses dis-
pensed in relation to the dispensing period, often called
the medication possession ratio (MPR)” [20]. This variable
is measured as the percentage of days the ITT medication
was available to the patient based on prescription ﬁll dates
over the 1-year post-period, and is a common proxy for
adherence when examining retrospective data [6, 21, 22].
As a test of the robustness of results, we also considered an
alternative proxy for adherence. Speciﬁcally, for each patient
the variable proportion of days covered (PDC) was also
constructed [23]. The PDC, like the MPR, is a measure of
the percentage of days a person received their ITT drug over
the year after index date. However, in contrast to the MPR,
the PDC does not allow for prescriptions to overlap. As a
result, the PDC, unlike the MPR, will always have an upper
bound of 1. The results reported here are not sensitive to
this alternative speciﬁcation and hence, results where PDC
was used as the dependent variable were not reported. It
should be noted, however, that neither the MPR nor PDC
can measure whether an individual took a prescription once
ﬁlled, whether an individual ﬁlled a prescription that wasMultiple Sclerosis International 3
Diagnosed with multiple sclerosis (MS) and receipto fa
disease modifying therapy( D M T ) ,w i t hﬁ rst such date
identiﬁed as index date
N = 75.488
No diagnosis of pregnancy over the time period from
6 months prior though 12 months post index date
N = 74,001
Continuous insurance coveragef rom 6 months prior
though 12 months post index date
N = 11,780
No diagnosis of depression orr eceipto fa n
antidepressant in the 6 months prior to
the index date
N = 4.779
Diagnosed with depression in the 6 months
prior to index date
N = 448
Figure 1: Inclusion/exclusion criteria.
written by their physician, orwhether the individual stopped
their ITT medication on or against physician advice.
2.4. Statistical Analyses. Descriptive statistics were compared
between groups using chi-square statistics. Multivariate
regressions were used to examine the impact of comorbid
depression aswell asmedical treatment fordepression on the
likelihood of a patient being adherent to their MS ITT DMT.
Speciﬁcally, ordinary least squares regressions were used to
examine the impact of depression on MPR when MPR was
measured as a continuous variables, while logistic models
were used to examine the association of depression on the
probability of achieving an MPR threshold of at least 80%
[24, 25].
In multivariate models it was hypothesized that, in addi-
tion to the factors that groups were matched on (age, sex,
region of residence, ITT DMT therapy, and year of index
date), other patient characteristics might also aﬀect adher-
ence. Speciﬁcally, these analyses also examined the asso-
ciation between patient insurance status, characteristics of
ITT medication,patientgeneralhealth,and patientdisability
level and adherence to ITT DMT. Characteristics of the ITT
medication that were examined were the amount of copay-
ment the individual was responsible for as well as whether
the ITT medication was delivered via mail order. It was
hypothesized that patientsrequired to make acopayment for
their medication may be less adherent to their medication
regimen while mail order delivery may be associated with
ease of use, and therefore may be associated with improved
adherence. Patient general health status was proxied by the
Charlson Comorbidity Index (CCI) [26, 27]. This measure,
which is well validated as an algorithm for predicting
hospital mortality and is often used in retrospective database
analyses, is constructed of a weighted average based upon
the receipt of diagnostic codes associated with 17 medical
conditions. Examples of conditions included in the CCI
include renal disease, myocardial infarction, malignancy,
liverdisease,cerebrovasculardisease,congestiveheartfailure,
dementia,anddiabetes[28].Finally,patientlevelofdisability
was proxied by the presence of musculoskeletal or medical
disabilities. These disabilities were proxied by examining
the presence of diagnoses for secondary conditions associ-
ated with muculoskeletal or medical disabilities, and prior
research has shown that these proxies are associated with
both the presence and severity of disabilities [29].
Allanalyses were conductedusing SASversion 9.3. Find-
ings of P values ≤ 0.05 were considered to indicate statisti-
cally signiﬁcant results.
3.Resultsand Discussion
3.1. Results: Descriptive Statistics. As expected, in all cases,
groups were identical in terms of the matching variables age,
sex, region of residence, ITT DMT, and year of index date.
WhencomparingtheMSonlygrouptopatientswithMSand
depression (Table 1), results revealed that patients diagnosed
with comorbid depression were signiﬁcantly less likely to
be insured via point-of-service insurance (13.30% versus4 Multiple Sclerosis International
Table 1: Patient characteristics: patients with MS Only compared to Patients with MS & Depression.
Characteristic
MS Only (N = 436) MS & Depression (N = 436)
χ2 statistic P value
N % N %
Characteristics matched on
Age N/A N/A
<35 54 12.39 54 12.39
35–44 107 24.54 107 24.54
45–54 171 39.22 171 39.22
55–64 95 21.79 95 21.79
65+ 9 2.06 9 2.06
Sex N/A N/A
Male 55 12.61 55 12.61
Female 381 87.39 381 87.39
Region N/A N/A
Northeast 53 12.16 53 12.16
North Central 124 28.44 124 28.44
South 166 38.07 166 38.07
West 93 21.10 93 21.10
Unknown 1 0.23 1 0.23
Year of index date N/A N/A
2004 66 15.14 66 15.14
2005 109 25.00 109 25.00
2006 109 25.00 109 25.00
2007 129 29.59 129 29.59
2008 23 5.28 23 5.28
ITT DMT N/A N/A
Avonex 97 22.25 97 22.25
Betaseron 51 11.70 51 11.70
Copaxone 198 45.41 198 45.41
Rebif 78 17.89 78 17.89
Tysabri 12 2.75 12 2.75
Other characteristics
Insurance status
Comprehensive 58 13.30 43 9.86 2.52 0.112
Health maintenance org 80 18.35 90 20.64 0.73 0.393
Point-of-service 99 22.71 58 13.30 13.06 <0.001
Preferred provider org 191 43.81 226 51.83 5.63 0.018
Other 8 1.83 19 4.36 4.63 0.032
Copayment with ITT drug 370 84.86 340 77.98 6.82 0.009
Mail order for ITT drug 145 33.26 119 27.29 3.67 0.055
Preperiod Charlson score
0 331 75.92 271 61.16 19.31 <0.001
1-2 93 21.33 132 30.28 9.11 0.003
3+ 12 2.75 33 7.57 10.33 <0.001
Preperiod disability proxies
Muscoloskeletal 181 41.51 262 60.09 30.10 <0.001
Medical 137 31.42 210 48.17 25.51 <0.001Multiple Sclerosis International 5
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Patients with MS and depression, compared to those with MS
only, were 44.8% (100-0.552) less likely to achieve a MPR
threshold of at least 80% with their MS medication. Patients with
comorbid depression who were treated with an antidepressant
for at least 6 months, compared to those treated with
an antidepressant for <6 months, were 116.6% (2.16–1) more
likely to achieve an MPR threshold of at Least 80%.
Figure 2: Impact of depression on probability of achieving MPR
threshold of 0.80.
22.71%; P<0.01), but signiﬁcantly more likely to be in-
sured via a preferred provider organization (51.83% versus
43.81%; P = 0.02) or to have “other” insurance (4.36%
versus1.83%;P = 0.03).Inaddition,patientswith comorbid
depression were less likely to have a copayment associated
with theirindex ITT medicationprescription (77.98%versus
84.86%; P = 0.01). Comparing patients with MS only to
thosewithMSanddepressionrevealedsigniﬁcantdiﬀerences
in both general health and functional limitations between
the two groups, with patients with comorbid depression
generally in poorer health. For example, patients diagnosed
with comorbid depression were less likely to have a Charlson
score of 0 (62.18% versus 75.92%; P<0.01) and more likely
to have a Charlson score of 1-2 (30.28% versus 21.33%; P<
0.01)or3 ormore (7.57% versus2.75%;P<0.01).Similarly,
patients with comorbid depression were signiﬁcantly more
likely to be diagnosed with a musculoskeletal limitation
(60.09% versus 41.51%; P<0.01) or medical limitation
(48.17% versus 31.42%; P<0.01).
In contrast to the comparison of patients with MS Only
to those with MS and depression, comparisons between
patients with MS and comorbid depression treated and
untreated with antidepressants revealed few diﬀerences. For
example, Table 2 compared patients diagnosed with depres-
sion who did not receive an antidepressant to those patients
who were both diagnosed with depression and received at
least one prescription for an antidepressant. There were
no statistically signiﬁcant diﬀerences found among these
two groups when comparing insurance status, copayment
or mail order status, CCI, or disability proxies (Table 2).
Similarly, comparing patients who received at least 6 months
of an antidepressant to individuals who received less than
6 months of an antidepressant (Table 3) revealed few diﬀer-
ences between the two groups.
3.2. Results: Ordinary Least Squares Regressions. Table 4
shows the results of the ordinary least squares regression
models that examine the association between comorbid
depression and patient adherence to ITT DMT for MS.
Comparing patients with Ms only to those with MS and
depression, results indicate that, after controlling for patient
insurance type, characteristics of initial DMT dispensed,
patient general health, and functional limitations, patients
with comorbid depression had a 10% lower MPR score than
those without comorbid depression (coeﬃcient = −0.10;
P<0.01). Results also reveal that patients with health-
maintenance insurance, compared to those with a preferred
provider organization had signiﬁcantly lower medication
adherence (coeﬃcient = −0.10; P = 0.02) while patients
who had a copayment associated with their ITT DMT had
signiﬁcantlyhighermedicationadherence(coeﬃcient=0.06;
P = 0.05).
Comparing patients diagnosed with depression but un-
treated to those both diagnosed and treated with an antide-
pressant revealed no signiﬁcant association between treat-
ment for depression with antidepressants and patient adher-
ence to their MS therapy (coeﬃcient = 0.07; P = 0.52).
However, patients treated with an antidepressant for at least
6 months compared to those treated for less than 6 months
have, on average, a 12-point higher MPR (coeﬃcient = 0.12;
P = 0.05) after controlling for insurance type, characteristics
of initial DMT dispensed, and patient general health and
functional limitation.
3.3. Results: Logistic Models. In addition to examining the
impact of depression on MPR levels, Figure 2 examines how
comorbid depression aﬀects the probability of achieving
a threshold of at least 80%. These results are generally
consistent with the results from the ordinary least squares
regression which examine MPR as a continuous variable.
Speciﬁcally, results from these multivariate logistic models
indicate that patients who were depressed (based upon
either diagnosis or diagnosis and receipt of antidepressant)
were 45% less likely to achieve an MPR threshold of 80%
(odds ratio (OR) 0.55; 95% conﬁdence interval (CI) 0.42–
0.74). An examination of the subset of patients with both
MS and depression revealed that those treated with an
antidepressant, irrespective of length of treatment, had no
signiﬁcant diﬀerence in the likelihood of achieving an MPR
threshold of 80% (OR = 1.32; 95% CI 0.50–3.48). However,
those treated with an antidepressant for at least 6 months
were twice as likely to reach an MPR threshold of 80% with
theirDMT,comparedtothosetreatedwith anantidepressant
for less than 6 months (OR = 2.17; 95% CI 1.07–4.39).
3.4. Robustness of Results. As a test of the robustness of
the results, alternative speciﬁcations were also examined.
First, we constructed an alternative model that allowed for
patient age, sex, region of residence, and ITT medication to
be explicitly included in the multivariate analyses. Second,
as discussed above, adherence was also proxied by the
proportion of days covered. Third, to examine the impact of
the relatively small sample when comparing those patients6 Multiple Sclerosis International
Table 2: Patient characteristics: MS patients diagnosed with depression but untreated compared to MS patients diagnosed with depression
who received an antidepressant.
Characteristic
Dx Depression (N = 38) Dx & Rx Depression (N = 38)
χ2 statistic P value
N % N %
Characteristics matched on
Age N/A N/A
<35 1 2.63 1 2.63
35–44 8 21.04 8 21.04
45–54 19 50.00 19 50.00
55–64 10 26.32 10 26.32
65+ 0 0 0 0
Sex N/A N/A
Male 2 5.26 2 5.26
Female 36 94.74 36 94.74
Region N/A N/A
Northeast 3 7.89 3 7.89
North Central 13 34.21 13 34.21
South 12 31.58 12 31.58
West 10 26.32 10 26.32
Unknown 0 0 0 0
Year of index date N/A N/A
2004 6 15.79 6 15.79
2005 11 28.95 11 28.95
2006 10 26.32 10 26.32
2007 10 26.32 10 26.32
2008 1 2.63 1 2.63
ITT DMT N/A N/A
Avonex 12 31.58 12 31.58
Betaseron 2 5.26 2 5.26
Copaxone 19 50.00 19 50.00
Rebif 4 10.53 4 10.53
Tysabri 1 2.63 1 2.63
Other characteristics
Insurance status
Comprehensive 6 15.79 4 13.16 0.11 0.744
Health maintenance org 5 13.16 9 23.68 1.40 0.236
Point-of-service 6 15.79 7 18.42 0.93 0.761
Preferred provider org 20 52.63 16 42.11 0.84 0.358
Other 1 2.63 1 2.63 N/A N/A
Copayment with ITT drug 29 76.32 29 76.32 N/A N/A
Mail order for ITT drug 13 34.21 10 26.32 0.56 0.454
Preperiod Charlson score
0 23 60.53 21 55.26 0.22 0.642
1-2 11 28.95 15 39.47 0.93 0.334
3+ 4 10.53 2 5.26 0.72 0.395
Preperiod disability proxies
Muscoloskeletal 25 65.79 24 63.16 0.06 0.811
Medical 16 42.11 18 47.37 0.22 0.645Multiple Sclerosis International 7
Table 3: Patient characteristics: MS patients treated with antidepressants for at least 6 months compared to MS patients treated with
antidepressants for less than 6 months.
Characteristic
Treated less than guidelines (N = 71) Treated according to guidelines (N = 71)
χ2 statistic P value
N % N %
Characteristics matched on
Age N/A N/A
<35 5 7.04 5 7.04
35–44 17 23.94 17 23.94
45–54 32 45.07 32 45.07
55–64 17 23.94 17 23.94
65+ 0 0 0 0
Sex N/A N/A
M a l e 11 . 4 111 . 4 1
Female 70 98.59 70 98.59
Region N/A N/A
Northeast 5 7.04 5 7.04
North Central 21 29.58 21 29.58
South 30 42.25 30 42.25
West 15 21.13 15 21.13
U n k n o w n 0000
Year of index date N/A N/A
2004 6 8.45 6 8.45
2005 17 23.94 17 23.94
2006 15 21.13 15 21.13
2007 28 39.44 28 39.44
2008 5 7.04 5 7.04
ITT DMT N/A N/A
Avonex 11 15.49 11 15.49
Betaseron 3 4.23 3 4.23
Copaxone 44 61.97 44 61.97
Rebif 13 18.31 13 18.31
T y s a b r i 0909
Other characteristics
Insurance status
Comprehensive 6 8.45 6 8.45 N/A N/A
Health maintenance org 16 22.54 10 14.08 1.70 0.193
Point-of-service 10 14.08 6 8.45 1.13 0.288
Preferred provider org 39 54.93 45 63.38 1.05 0.306
Other 0 0 4 5.63 4.12 0.043
Copayment with ITT drug 61 85.92 54 76.06 2.24 0.134
Mail order for ITT drug 23 32.39 22 30.99 0.03 0.857
Preperiod Charlson score
0 45 63.38 40 56.34 0.73 0.392
1-2 20 28.17 26 36.62 1.16 0.282
3+ 6 8.45 5 7.04 0.09 0.754
Preperiod disability proxies
Muscoloskeletal 46 64.79 48 67.61 0.13 0.723
Medical 35 49.30 42 59.15 1.39 0.2388 Multiple Sclerosis International
Table 4: Ordinary least squares regression results dependent variable: MPR.
Variable
MS Only versus MS & Depression Dx Depression versus Dx & Rx
Depression
Rx Depression- ≥6Mo
Antidepressants versus <6Mo
Coeﬀ P value Coeﬀ P value Coeﬀ P value
Intercept 0.71 <0.001 0.64 0.047 0.47 <0.001
Insurance typea
HMO −0.10 0.022 −0.14 0.509 -0.16 0.200
POS −0.02 0.665 −0.07 0.731 0.02 0.901
PPO 0.01 0.890 0.12 0.491 0.02 0.860
Other −0.002 0.974 −0.27 0.523 0.08 0.693
Medication dispensing
Copayment 0.06 0.047 −0.06 0.680 0.10 0.213
Mail order 0.05 0.051 0.02 0.909 0.08 0.216
Preperiod Charlson scoreb
1-2 0.01 0.738 0.09 0.521 0.06 0.379
3+ −0.04 0.467 0.04 0.853 0.09 0.422
Preperiod ADL proxies
Musculoskeletal 0.02 0.440 −0.03 0.828 0.06 0.294
Medical 0.02 0.448 0.10 0.419 −0.01 0.889
Preperiod depression
Any −0.10c <0.001 — — — —
Dx & Rx — — 0.07d 0.518 — —
Rx for at least 6 months — — — — 0.12e 0.049
Adjusted R2 0.05 0.08 0.06
aReference group: Comprehensive insurance.
bReference group: Charlson score of 0.
cReference group: patients with MS and no diagnosis of depression or receipt of an antidepressant.
dReference group: patients diagnosed with depression who did not receive an antidepressant.
eReference group: patients diagnosed with depression who were treated with an antidepressant for less than 6 months.
diagnosed with depression but untreated to those diagnosed
with depression who received an antidepressant, the analysis
alsoexaminedthissubgroupwithoutthereductionofsample
size that is the result of matching the two cohorts; none of
these modiﬁcations resulted in any signiﬁcant changes in the
results reported.
3.5. Discussion. Focused on a population consisting entirely
of patients with MS, this analysis was designed to determine
the impact of comorbid depression on adherence to DMT.
This study also sought to determine the impact of antide-
pressant therapy on adherence to DMT among patients with
MSand comorbiddepression. Thisanalysis producedseveral
noteworthy results.
First, patients diagnosed with comorbid depression were
sicker than those without comorbid depression, as indicated
by their likelihood of a higher score on the Charlson Comor-
bidityIndex(seeTable 1),aswellastheirgreaterlikelihoodof
having a musculoskeletal limitation (60.09% versus 41.51%;
P<0.01) or any medical limitation (48.17% versus 31.42%;
P<0.01). This association between comorbid depression
and a larger burden of illness is consistent with research on
other disease states, research which has shown that patients
with diabetesand comorbiddepression havemore complica-
tionsrelativetodiabeticpatientswithoutdepression[30]and
that heart disease patients with comorbid depression have
greatermorbidityandmortalityrelativetotheircounterparts
without depression [31–37].
Second, patients with MS and comorbid depression had,
on average, a 10-point lower MPR and were approximately
half (45%) as likely to reach a threshold MPR level of 80%
relative to the matched cohort with MS without depression.
The strong association between depression and diﬃculty
with adherence was expected and was consistent with the
ﬁndings of earlier research conducted among patients with
MS [10, 13]. It also was consistent with research showing
t h en e g a t i v ee ﬀect of comorbid depression on adherence
to therapy for other diseases, including hypertension [38],
diabetes [10, 11], and heart disease [39, 40]. While previous
research among patients with MS has shown comorbid
depression to be associated with adherence diﬃculties [10,
13], our research expands the literature by quantifying the
adherence gap between those MS patients with comorbid
depression compared to those without depression.
Third, results from this analysis revealed no signiﬁcant
diﬀerence in adherence to DMT therapy when comparingMultiple Sclerosis International 9
patients diagnosed with depression that were not treated
with an antidepressant to those both diagnosed and treated
for depression. However, among patients with comorbid
depression, those who received at least a 6-month supply of
antidepressants had, on average, a 10-point higher MPR and
were more than twice as likely to reach an MPR threshold
of 80% relative to those who ﬁlled their antidepressant
medication prescription for less than a 6-month period. Sig-
niﬁcantly, in our study, merely having a prescription for
an antidepressant had no signiﬁcant impact on DMT adh-
erence.Instead, thepositiveimpact ofantidepressant therapy
on DMT adherence was observed only among patients
whose antidepressant therapy extended for at least 6 months.
This ﬁnding supports previous research conducted among
patients diagnosed with diabetes, which showed that antide-
pressant therapy improved adherence to diabetes treatment
and medical outcomes [41]. However, caution must be
taken when interpreting this ﬁnding since results are also
consistent withthehypothesis thatpatientswho areadherent
to their antidepressant therapy are generally more compliant
at taking their medications and hence, more likely to be
adherent to their DMT as well.
3.6.Limitations. Aswith any research, theﬁndings presented
here should be interpreted within the context of the limita-
tions of the study design. First, this analysis was conducted
using an administrative claims database and included only
patients with medical and outpatient prescription drug ben-
eﬁt coverage. The results, therefore, may not generalize well
to other populations. Second, it is less rigorous to rely upon
diagnostic codes rather than formal diagnostic assessment
for identifying patients or for measuring patient general
health and functional limitations. For example, our reliance
on diagnostic claims and the criteria utilized for identifying
patients with depression resulted in approximately 6% of
our MS cohort with comorbid depression while previous
research hasshown thatupto 50%ofMSpatientsexperience
comorbid depression [14, 15]. Third, this analysis used
MPRs and PDCs to measure medication adherence. Such
measures are unable to identify actual drug-taking behavior
or patient adherence to ﬁlling written prescriptions. Fourth,
the database was unable to capture other information, such
as patient personality type, caregiver support, and type of
MS, that may also impact outcomes. Finally, this study
focuses on a subset of individuals who were diagnosed with
depression prior to receipt of a DMT for MS. The results,
therefore, may not apply to individuals who are diagnosed
with depression subsequent to initiation on treatment for
MS.
4.Conclusions
In conclusion, this study indicates that those with MS and
comorbid depression are sicker and approximately only half
as likely to be adherent to their disease-modifying therapy
relative to patients with MS without comorbid depression.
This analysis also shows were no signiﬁcant diﬀerence in
DMT adherence when comparing patients diagnosed with
depression but not treated with an antidepressant to those
both diagnosed and treated for depression. However, those
with MS and comorbid depression who take antidepressants
for at least 6 months are more than twice as likely to
be adherent to their DMT relative to those with MS and
comorbid depression who do not remain on antidepressant
therapy for at least 6 months. Future work should focus
on examining these results with alternative data sources
and improving our understanding of the relationship be-
tween adherence to antidepressant therapy and adherence to
DMT.
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